May 2025 in “The Journal of Rheumatology” Purpura fulminans can signal underlying autoimmune disorders, not just infections.
May 2025 in “The Journal of Rheumatology” Lupus patients in Ghana face healthcare challenges, and the Oyemam Autoimmune Foundation is working to improve awareness and support.
May 2025 in “The Journal of Rheumatology” Bullous lupus can cause severe esophageal issues but responds well to corticosteroids and azathioprine.
May 2025 in “The Journal of Rheumatology” Correct diagnosis is crucial for treating overlapping conditions like NMOSD and SLE effectively.
May 2025 in “The Journal of Rheumatology” Middle-aged women with dilated cardiomyopathy should be screened for antiphospholipid syndrome.
May 2025 in “The Journal of Rheumatology” Early recognition and a team approach are crucial for managing diffuse alveolar hemorrhage in antiphospholipid syndrome.
May 2025 in “The Journal of Rheumatology” SLE can cause unusual gastrointestinal symptoms, and immunosuppressive therapy can be effective.
November 2024 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in safe medication use and interdisciplinary collaboration is key to reducing antimicrobial resistance.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
February 2024 in “Digital Library of Theses and Dissertations (Universidade de São Paulo)” Argan, avocado, and coconut oils are absorbed into hair, improving hydration and protection.
January 2024 in “Surgical & Cosmetic Dermatology” Exosomes may help treat skin diseases and improve skin rejuvenation.
September 2022 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica” Skin symptoms appear in up to 20% of Covid-19 cases.
April 2015 in “Journal of Evolution of Medical and Dental Sciences” People with autoimmune skin diseases often have hearing problems and should get their hearing checked early.
April 2024 in “Expert opinion on investigational drugs” JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
16 citations
,
August 2023 in “JAAD Case Reports” JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
January 2026 in “Journal of Clinical Medicine” Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
December 2024 in “Quality in Sport” PCOS involves immune system issues and inflammation, possibly leading to autoimmune diseases.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
28 citations
,
January 2009 in “Cellular & Molecular Biology Letters” DHT deficiency increases iNOS expression in rat testis and epididymis.
5 citations
,
March 2023 in “International Journal of Trichology” Alopecia areata patients may have higher cardiovascular risk factors, so screening for metabolic syndrome components is suggested.
4 citations
,
July 2023 in “Frontiers in Microbiology” HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.
1 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Farudodstat may effectively treat alopecia areata without harmful side effects.
September 2025 in “Wound Repair and Regeneration” GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
June 2025 in “Patient Preference and Adherence” Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.
April 2025 in “BMC Immunology” Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.
January 2025 in “Dermatologic Therapy” Alopecia areata patients don't have increased atherosclerosis risk, but may have higher cardiovascular risk due to smoking, blood sugar, and blood pressure.
August 2024 in “International Journal of Molecular Sciences” Mesenchymal Stem Cell therapy shows promise for treating hair loss in Alopecia Areata.
25 citations
,
November 2020 in “Cell Reports Medicine” Developing human skin has immune cells with memory-like features.